MEET THE TEAM
Mr. Rai is a founder and serves as CEO and Chairman of Cancer Check Labs. Mr. Rai has been involved in the development of its technology since 2010.
The extraordinary increase in circulating tumor cell (CTC) capture capability utilized by Cancer Check Labs presents opportunities to realize previously inconceivable diagnostic and therapeutic applications in oncology and represents a disruptive breakthrough in cancer technology.
Mr. Rai is passionate about curing cancer because he lost his younger sister, his only sibling, to cancer and has served since 2012 as the President of CureSonia, a 501(c)(3) nonprofit organization. Cure Sonia battles cancer through funding research programs at leading centers such as Stanford, USC, MD Anderson, and the City of Hope, providing financial patient assistance to underprivileged families undergoing treatment, and supporting bone marrow drives by having run over 300 drives across 60 cities directly registering over10,000 donors across the country making it one of the largest global bone marrow registrars. Mr. Rai is also the President and founder of Save a Firefighter, another 501(c)(3) nonprofit organization that provides free cancer screening services to firefighters across the country because they suffer from up to 3x the incidence of cancer as compared to the normal population given the hazardous exposure they endure as firs responders to serve our community: shockingly, cancer represents 72% of line of duty death for firefighters. Mr. Rai was also nominated in 2022 for the National Board of Leukemia& Lymphoma Society (LLS) because of his contributions to combatting cancer.
Mr. Rai previously was the founder, CEO, and Chairman of Mobclix, the leading real-time bidding (RTB) mobile advertising exchange that at the advent of thein-application (Apple App Store and Google Play Store) advertising market grew to over 15 Billion monthly mobile ad impressions, 180,000 publisher partners, and a $50 Million annual revenue run rate in under two years catalyzing the acquisitions by Velti and subsequently Telefonica (NYSE: TEF).
Mr. Rai has over twenty years of venture capital, private equity, and hedge fund experience at firms including Riverside Partners, Crosslink Capital, and American Industrial Acquisition Corporation. During that time, he has acquired and invested in dozens of companies. A select few include LSTAT (Life Support for Trauma and Transport, an ICU built into a smart stretcher) which was acquired from Northrop Grumman (NYSE: NOC), to save lives on the battlefield during the golden hour (the first 60 minutes from point of injury); MagmaDesign Automation, an electronic design automation software tool for deep sub-micron semiconductor development, that went public (NASD: LAVA) and was subsequently acquired by Synopsys (NASD: SNPS); and National Display Systems, a leader in flat panel surgical displays subsequently acquired by Novanta (NASD:NOVT).
Mr. Rai is an active angel investor and has been involved in startups throughout his career. He has served on several company Boards including Fastbite, a rapid, on-demand food delivery service acquired by Square (NASD:SQ); Muzik, a leading developer of smart wearable technology solutions; Braidio, a leading enterprise software platform to enable knowledge sharing in the workplace; and OpenSense, an innovative enterprise software company backed by Bloomberg that enhances email to become branded sales and marketing collateral.
Mr. Rai has been a judge and mentor for numerous business plan competitions including those held by Stanford Bases and the University of California at Berkeley; he has been featured as a guest lecturer for courses at the University of California at Berkeley and Boston College and has been featured as a speaker and panelist for various organizations including Ernst &Young, Asian Venture Capital Journal (AVCJ), Opal Financial Group, and TIE (The Indus Entrepreneurs) where he has served as a Charter Member. Mr. Rai holds a Bachelor of Science and Engineering degree in Electrical Engineering and Computer Science from the University of California at Berkeley, where he graduated early as a Regent Scholar.
Mr. Cahan is a founder and serves as President and Chief Operating Officer of Cancer Check Labs. Mr. Cahan has been involved with and personally invested in the development of the technology utilized by Cancer Check Labs since 2011. Mr. Cahan has extensive operational experience in healthcare, healthcare software, and systems, data management including HIPAA, supply chain, inventory management, and automated scheduling protocols within a variety of healthcare environments including hospitals, clinical centers, surgical facilities, and labs.
Previously, Mr. Cahan also served as Interim CIO for Jackson Healthcare, a multi-billion-dollar health conglomerate that serves over 7 million patients in over 1,300 facilities. At Jackson Healthcare, Mr. Cahan rebuilt and reorganized the top leadership of the IT and software development departments to develop a new strategic project roadmap that enabled the company to successfully grow into one of Atlanta’s largest private companies. Prior, Mr. Cahan was also a founder and Chief Technical Officer (CTO) of Care Logistics, a Jackson Healthcare subsidiary. Mr. Cahan oversaw the product from inception and creation to commercialization and steady growth. Care Logistics managed patient flow and throughput processing in hospital operating systems to achieve operational efficiency across all departments simultaneously.
Prior, Mr. Cahan was a founder and VP of Research and Technology of Surgical Information Systems (SIS), a software solutions company for surgical environments. SIS dominates its industry with 80% of Ambulatory Surgical Centers (ASCs), which includes over 10,000 operating rooms (ORs) across 2,300 healthcare facilities, choosing SIS. As a member of the Executive Board, Mr. Cahan was integral to steering the direction of the company. Mr. Cahan built the system architecture, developed a significant portion of the initial codebase, guided the commercialization strategy for its market entry, and profitably grew the company to over 100 people. After building SIS into a stable cash flow-positive business, Mr. Cahan also helped to facilitate a company exit for $65 Million.
Mr. Cahan served as a Partner at Dane Investment Group. Given Mr. Cahan’s broad industry and operational experience, while at Dane, Mr. Cahan was asked to turn around Dexter’s Farm, one of Georgia’s largest produce, egg, and dairy distributors suffering from a lack of workflow processes and actionable data integration. Mr. Cahan was appointed CEO, purchased the company through a leveraged buy-out (LBO) during an economic downturn, and grew revenues from $15 Million to $44 Million generating over $3 Million in profits turning around the company in less than two years.
As a serial entrepreneur and ardent angel investor, who has been starting his businesses since he was seven years old, Mr. Cahan draws on his wealth of experience to architect and build technology companies. He has provided seed capital, mentoring, business planning, and strategic advice to companies developing healthcare software, medical devices, cloud solutions, data analytics, automated marketing software, and media streaming services. He has advised and chaired several boards throughout his career.
Cahan studied Computer Science at Drexel University. Mr. Cahan enjoys options trading and is an avid bridge player who has won two National Titles.
Mr. Ciardella is the Chief Financial Officer of Cancer Check Labs. Mr. Ciardella brings over 40 years of finance, compliance, and operations experience to the company.
Mr. Ciardella held positions at hi-tech computer and medical companies such as ZOLL Medical Corporation (Division CFO from 2014 to 2023), NDS Surgical Imaging (CFO from 2004 to 2013), and Dolch Computer Systems (CEO, COO, CFO from 1990 to 2004). Mr. Ciardella previously has experience at Hewlett Packard (NYSE: HPQ), National Semiconductor (NYSE: NSM), and Deloitte and Touche. Mr. Ciardella’s experience includes public accounting, GAAP, compliance, and corporate securities. Further, Mr. Ciardella has extensive experience establishing, building, and managing global manufacturing operations.
Mr. Ciardella has raised over $100 million of equity capital, led structured debt financings, and equipment financings, grown successful management teams, scaled up operations, expanded several companies and divisions globally, and consummated multiple liquidity events exceeding board, investor, and management expectations. Mr. Ciardella grew up in Palo Alto, California, and witnessed the early days of Silicon Valley and the technological changes that shaped it. From startups to Fortune 500 companies, Mr. Ciardella helped entrepreneurs grow successful companies, build scalable infrastructure, motivate management teams, and maximize shareholder value.
Mr. Ciardella holds a BS degree in Accounting from California State University.
Mr. Kanakia serves as Chief Strategy Officer for Cancer Check Labs. He brings over 20 years of professional experience as a strategic leader for global banks, consulting firms, and financial service organizations, specializing in strategic planning, risk management, organizational efficiency, and enterprise-wide automation.
Prior to joining Cancer Check Labs, Kanakia was a Senior Vice President at Bank of America where over his tenure he led teams involved in capital markets, credit cards, mortgages, wealth management, capital planning, risk, and compliance. During his tenure, he also oversaw model risk management reporting to the Board of Directors; trained hundreds of colleagues on risk management practices; and regularly assessed strategic opportunities to expand business lines and improve regulatory compliance processes.
Previously, Mr. Kanakia was an executive at Capital One where he managed teams involved in commercial lending, credit card underwriting, and capital planning. As a strategic leader, he served at the helm of teams responsible for modifying commercial loan pricing, as well as enhancing risk management procedures to align with industry best practices.
Mr. Kanakia began his career at KPMG where he served as a consultant to such leading Fortune 500 brands as Pfizer, General Electric, Haliburton, PepsiCo, and Hershey.
He holds a Masters in Operational Research from Columbia University and earned a bachelor's in economics from the University of California at Berkeley.
Lara Mehanna is the Chief Marketing Officer of Cancer Check Labs. She has over 25 years of marketing experience, during which she has launched numerous innovative technologies and brought brand messages to market across channels and platforms on behalf of publishers, brands, agencies, and tech companies.
Before joining Cancer Check Labs, Ms. Mehanna spent more than six years at National CineMedia, where she built the market for consumer digital products and leveraged digital data to connect brands to movie audiences across devices. She also played a pivotal role in launching an influencer marketing program to help small and medium-sized businesses grow their brand presence on social platforms.
Previously, Ms. Mehanna led sales strategies, go-to-market development, and omnichannel media approaches for DataXu and Jumptap. Earlier in her career, Ms. Mehanna led the global search business for AOL. During her tenure during the early days of the Internet, she forged media partnerships and spearheaded consumer search solutions, achieving a first-of-its-kind, revenue-generating business offering.
A breast cancer survivor, Ms. Mehanna has been recognized as a Ford Warrior in Pink Model of Courage for supporting, inspiring, and connecting with women in her community battling breast cancer. She has launched fundraising activities for organizations such as Cancer Couch and shared her experience with yoga and its impact on her cancer journey at Wanderlust retreats.
Ms. Mehanna serves on the board of She Runs It, where she regularly mentors the next generation of marketers.
Dr. Charles Matthews, a board-certified radiation oncologist, serves as Chief Medical Officer for Cancer Check Labs, collaborating actively with the organization and its partners.
He trained at Johns Hopkins University and holds a dual MD/MBA degree from there, specializing in radiation oncology. Dr. Matthews is also a graduate of Duke University, with notable achievements including receiving a NIH Medical Student Grant. Currently, he serves as Medical Director of Hospital Cancer Services for Christus St. Michael, W. Temple Webber Cancer Center.
His responsibilities encompass overseeing medical administration, leading tumor boards, implementing standards of care, and conducting specialty training and education.
Dr. Matthews is widely published and draws national audiences in radiation oncology, with particular interests in breast, genitourinary, and thoracic cancers.
Scientific Advisory Board
Dr. Arun Balakumaran, MD, Ph.D., serves as Advisory Chairman of the Scientific Advisory Board at Cancer Check Labs, where he contributes his deep expertise to advance the company’s mission. In his role as Chief Medical Officer at Replay, a pioneering company at the intersection of genomics, medicine, and technology, Dr. Balakumaran leads with innovation and strategic insight.
Dr. Balakumaran's extensive background includes transformative roles, such as the former Chief Medical Officer at Allogene and the Product Development Lead at Merck. At Merck, he was recognized as a Merck Distinguished Scientist and played a pivotal role in the development of Keytruda, a broad-spectrum cancer drug. Trained in clinical and laboratory research at the National Institutes of Health (NIH), he has built a robust foundation in medical science.
Notably, Dr. Balakumaran is celebrated for his breakthroughs in oncologic cell therapy and his instrumental role in securing FDA approvals for key cancer therapies, including Pembrolizumab. Beyond Cancer Check Labs, he also lends his expertise to another innovative diagnostic company as a scientific advisory board member, driving the development of revolutionary diagnostic technologies.
With over 40 peer-reviewed publications in eminent scientific journals, Dr. Balakumaran combines a creative mind with a collaborative spirit, significantly enhancing the early detection and treatment of cancer.
Dr. Raj Attariwala, MD, PhD, FANM, FRCPC, is a world-renowned expert in whole body radiology and nuclear medicine. He is a coauthor of Oncorads – a global standardized MRI technique for cancer screening and the emeritus founder and creator of the Prenuvo scan and report. His expertise in PETCT and whole body MRI redefined imaging of early cancer detection and preventative healthcare.
Dr. Attariwala holds dual board certifications in Radiology and Nuclear Medicine. His training includes prestigious institutions such as Memorial Sloan Kettering, UCLA, and USC. He earned a PhD in Biomedical Engineering from Northwestern University and has an extensive publication record in peer-reviewed medical and scientific journals.
His innovative work in molecular imaging, artificial intelligence-driven diagnostics, and precision medicine has enabled early detection of cancer and other life-threatening diseases for thousands of patients. Throughout his career, he has pushed the boundaries of diagnostics, emphasizing the importance of early detection before symptoms arise, when conditions are most treatable. His work has been widely recognized in the medical community for its role in enhancing preventative healthcare and improved patient outcomes.
Beyond his technological innovations, Dr. Attariwala is a sought-after educator, speaker, and thought leader in diagnostic imaging, longevity science, and precision health. His insights into whole-body imaging and early cancer detection have influenced the way clinicians and researchers approach proactive medicine. Dedicated to reshaping modern disease prevention, he continues to drive advancements in cancer screening, emphasizing early detection as the foundation of longevity-focused healthcare.
Dr. Moro Salifu is the Chief of the Division of Nephrology and Director of the Kidney Transplant Program at SUNY Downstate. He joined SUNY Downstate after completing medical school in Turkey to pursue residency training in internal medicine. During his internship, Dr. Salifu quickly excelled, earning fellowships in kidney diseases, kidney transplantation, and interventional nephrology, where he graduated as a stellar scholar in all three subspecialties.
Throughout his residency and fellowship training, Dr. Salifu consistently won annual awards in the basic science category in the Department of Medicine for six consecutive years. He also received four consecutive awards from the American College of Physicians. Following his fellowship, Dr. Salifu was retained by SUNY Downstate as an Assistant Professor in 2001. He rapidly advanced to Associate Professor and then to Professor within seven years, a milestone attributed to his outstanding original research contributions, clinical expertise, and dedication to medical education.
During this period, Dr. Salifu also earned two master's degrees—one in public health and another in healthcare business administration. He has been directing the nephrology fellowship training program since 2001 and took on the roles of Chief of Nephrology and Director of the Transplant Program in 2008. These positions were critical to the restructuring of the kidney dialysis and transplant programs at SUNY Downstate.
Dr. Salifu is a recipient of numerous grants and has published extensively. He is an active member and journal reviewer for many nephrology and transplant societies and has served on various local and national professional committees. Additionally, he is a fellow of the American College of Physicians. His research interests focus on chronic kidney disease (CKD) progression, vascular biology, and kidney transplant outcomes.
Dr. Ingrid Swanson Pultz is a Translational Advisor at the Institute for Protein Design (IPD). She was previously the Chief Scientific Officer of PvP Biologics, an IPD spin-out company acquired by Takeda Pharmaceuticals in 2020, and also served as the CEO of PvP during its early years. Dr. Pultz was formerly a Translational Investigator and Senior Research Fellow at the IPD, where she focused on developing the enzyme technology that formed the foundation of PvP's innovations.
Throughout her career, Dr. Pultz has received several competitive grants and awards for her work, including being named Health Innovator of the Year by Health Innovation Northwest in 2016. She completed her graduate work on bacterial second messenger systems under the mentorship of Dr. Sam Miller at the University of Washington’s Department of Microbiology. During her graduate studies, Dr. Pultz was honored with the Neal Groman Award for Excellence in Teaching and founded the UW’s International Genetically Engineered Machine (iGEM) team.
In her current role at the IPD, Dr. Pultz guides the translation of emerging technologies from the academic laboratory into practical applications, helping to bridge the gap between research and commercialization.
Dr. Hameed graduated from Rawalpindi Medical College in 1984, where he laid the foundation for a career in medicine that has spanned several decades. With a strong focus on patient care and medical excellence, Dr. Hameed has dedicated his professional life to the fields of Internal Medicine and Infectious Disease.
Currently, Dr. Hameed practices in Brooklyn, NY, and also serves patients at an additional location, bringing his expertise to a diverse patient population. His work involves diagnosing and treating a wide range of conditions, with a particular emphasis on managing infectious diseases, a field that requires continuous learning and adaptation to new challenges in medicine.
Dr. Hameed is affiliated with Kingsbrook Jewish Medical Center, a respected institution known for its comprehensive healthcare services. His affiliation with Kingsbrook Jewish Medical Center allows him to collaborate with other specialists and access the latest medical technologies, ensuring that his patients receive the highest standard of care. Throughout his career, Dr. Hameed has been committed to advancing his knowledge and staying at the forefront of medical developments, reflecting his deep commitment to his patients and his profession.
A fifth-generation Californian, Dr. Bachelor was born in San Francisco, grew up in Sacramento, then attended college at Stanford University and graduated with great distinction. He received his medical degree from the University of California at San Francisco and went on to complete his residencies in General Surgery and Plastic Surgery at Stanford University. Dr. Bachelor is board-certified by the American Board of Plastic Surgery.
Practicing in the California towns of Pleasanton and Danville, Dr. Bachelor offers a full range of services, including non-surgical cosmetic procedures. Dr. Bachelor has performed over 10,000 facial rejuvenation procedures with advanced dermal fillers such as Juvederm, Restylane, Sculptra Aesthetic, ArteFill, and Perlane, as well as Botox and Dysport.
Dr. Bachelor performs a host of plastic surgery procedures, including facial procedures such as facelift and eyelid lift (blepharoplasty) surgeries as well as body contouring enhancement surgery, including liposuction, abdominoplasty, breast reduction, breast augmentation, and tummy tuck.
Dr. Bachelor has been recognized as one of America’s Top Plastic Surgeons by the Consumers’ Research Council of America. He frequently lectures to fellow physicians in plastic surgery, and trains medical practitioners in advanced dermal filler injection techniques as a member of the National Education Faculty for Allergan. He is recognized by Allergan as a diamond Provider of Botox and Juvederm and by Galderma as a Gold Provider of Sculptra, signifying extensive experience with liquid facelift procedures.
A classically trained, award-winning portrait artist, Dr. Bachelor brings a special artistic sense to all of the surgical procedures he performs.
Dr. Kim de Mora is the Senior Cell Biologist at Cancer Check Labs, where he leverages over a decade of experience in scientific research, engineering, and medical innovation to develop impactful solutions addressing global health challenges. Throughout his career, Dr. de Mora has played a pivotal role in creating multiple medical technologies and devices, including the initial version of a cartridge-based renal dialysis system that evolved into Quanta Dialysis. This home hemodialysis console received FDA 510(k) clearance in December 2020, significantly advancing home treatment options for renal dialysis patients.
Previously, Dr. de Mora served as the Director of Development for the International Genetically Engineered Machines (iGEM) Foundation, where he led the judging of the world’s premier synthetic biology competition. He assembled a team of 165 judges to evaluate more than 300 teams from 42 countries, fostering innovation that resulted in the creation of over 150 companies, including billion-dollar enterprises like Ginkgo Bioworks, Benchling, and OpenTrons.
One of Dr. de Mora’s most notable contributions during his time with iGEM was the development of an award-winning arsenic biosensor system. His team genetically engineered a strain of E. coli to detect arsenic in drinking water, a critical public health issue, and produce a visible pH-color response. This groundbreaking work was featured in Wired Magazine and several books on synthetic biology, inspiring future iGEM teams to tackle other significant global challenges, such as plastic degradation in oceans and the rapid detection of pathogenic fungal infections.
Dr. de Mora also contributed to the field of synthetic biology through his work on BioBrick genetic regulatory measurement techniques during his Ph.D., which laid the foundation for the largest interlab measurement study in synthetic biology, involving over 200 labs worldwide. In his postdoctoral research, he developed an ex vivo zebrafish heart culture model and a high-throughput histological sectioning technique, further advancing biological research methodologies.
Recognized as a leader in his field, Dr. de Mora was selected as a Synthetic Biology Leadership Accelerator (Synbio LEAP) Fellow and awarded a Lessells Travel Scholarship by the Royal Society of Edinburgh, allowing him to visit Harvard Medical School. His illustrious career has also been profiled in Science Magazine. Dr. de Mora holds a Master’s degree in Mechanical Engineering and Management and was the first person in the United Kingdom to earn a Ph.D. in Synthetic Biology, both from the University of Edinburgh.
Longevity & Wellness Advisory Council
Dr. Cleaver serves as Council Chairman of the Longevity & Wellness Advisory Council for Cancer Check Labs. Dr. Cleaver is a fellow of the American Board of Anti-Aging/Regenerative Medicine (ABAARM), In addition to Dr. Cleaver’s board certification in Internal Medicine (ABIM), he is board certified in anti-aging and regenerative medicine and has achieved certification by the ABAARM in Advanced Metabolic Endocrinology specializing in bio-identical hormone therapy. As a faculty member at A4M and MMI, he lectures both nationally and internationally in longevity medicine, sports performance, and regenerative medicine. Board-certified in internal medicine and a rheumatologist he is an expert in medical ortho-biologic treatment of sports injuries and disorders of the musculoskeletal system.
He holds the position of adjunct clinical professor at George Washington School of Medicine where he has taught the exercise prescription component of the master's program in Integrative Medicine. He is a past member of the scientific advisory board and board of directors for the International Peptide Society, Dr. Cleaver lectures on the use of peptides in longevity, senolytic science, aesthetics, and hair restoration and actively trains medical professionals at Peptide Practices of America.
He has authored and published research and textbook chapters. While at the Cooper Clinic and Cooper Institute, he has conducted NIH research, funded by Homeland Security grants, assessing the health and developing fitness programs for first responders, focusing on first responders. He has written numerous articles for several international sports and anti-aging magazines. He co-authored the exercise and muscle health chapter for the George Washington Medical School Integrative Medicine textbook. He is a master trainer at TRAIN NOW MD, a highly sought-after hands-on training program in the field of regenerative and cosmetic medicine.
As a decellularized growth factors expert with 15 years of experience in regenerative aesthetics, he applies this cutting-edge regenerative medical science in the treatment of hair restoration and minimally invasive aesthetics – skin and face rejuvenation. In addition, he is a master trainer in Plasma Pen™ and PDO threads aesthetics, and body contouring and develops Plasma Pen™ and PDO thread techniques and protocols.
Elliot B Lander, M.D. F.A.C.S. is a Board-Certified Surgeon, Co-Founder, and Co-Medical Director of California Stem Cell Treatment Center, Cell Surgical Network.He was born in Los Angeles, California. He graduated Magna Cum Laude and Phi Beta Kappa from Occidental College with Distinction in Biochemistry. He attended medical school at the University of California, Irvine. He was a Clinical Assistant Professor of Urology at UC Irvine while in practice in Orange County for five years. During that time he was active in teaching residents and doing research.
Dr. Lander has been elected as a Fellow of the American College of Surgeons. He has served as Chief of Urology at Eisenhower Medical Center and Chief of Surgery at John F. Kennedy Hospital. Dr. Lander has been on staff at Eisenhower Medical Center for twenty years. He is also an Expert Reviewer in Urology for the California Medical Board. Dr. Lander is also doing clinical research on his patented liposome encapsulated pentosan for the treatment of interstitial cystitis and is the founder of Nanologix Research Inc. Dr. Lander is a pioneer in regenerative urology with publications on using stem cells to treat Peyronies Disease, Erectile Dysfunction, and Interstitial Cystitis. Also, one area of very special interest includes the study of the use of stem cells in developing cancer vaccines.
Dr. Lander is currently involved in IRB-approved translational stem cell treatment research at the California Stem Cell Treatment Center based in Rancho Mirage and Beverly Hills. Dr. Lander co-founded Cells on Ice® which is a cryobanking stem cell technology company. He is a founding member of the International Cell Surgical Society ICSS, a nonprofit organization supporting cell therapy research and education. ICSS supports Regenatrak™, which is an online regenerative medicine database tool used by clinicians to track clinical outcomes and adverse events from all over the globe.
Mark Carney, ND, LAc, graduated from Southwest College of Naturopathic Medicine and completed a residency in family medicine at the National College of Natural Medicine (NCNM). Additionally, he completed a Master of Science in Oriental Medicine from the International Institute of Chinese Medicine.
He has been in private practice since 2001, created and taught a Nature Cure course at NCNM, and served on the North American Board of Naturopathic Examiners (NABNE) for several years. He and his wife are cofounders of Thriveology, LLC, a holistic practice in Denver, Colorado. Carney has been featured many times in the media, including Fox News, National Public Radio (NPR), Naturally Savvy, and Sirius XM, and he often presents at local and national conferences as well as corporations.
Dr. Christopher Chun serves as a member of the Longevity and Wellness Advisory Council at Cancer Check Labs. Dr. Chun owns Epic Pain & Orthopedics, a leading pain management and functional medicine practice.
Dr. Chun's extensive training includes completing an Anesthesiology residency and ACGME accredited fellowship in Pain Management at Loma Linda University Medical Center. Dr. Chun is double-board certified in Anesthesiology and Interventional Pain Management with a sub-specialty certification in Pain Medicine by the American Board of Anesthesiology.
Dr. Chun's specific areas of interest are in Interventional Pain Management (injectables and procedural) and advancement in the field of Pain Management. Dr. Chun treats his patients using a multi-disciplinary approach to provide patient-specific compassionate care.
Dr. Chun’s goals for his patients are to diagnose correctly, for them to understand the source and reason for their pain, know the different treatment options to help treat that source of pain, help them to function and work better, and obtain a better and improved quality of life.
Dr. Andrew H. Heyman leads the Integrative and Metabolic Medicine Center at The George Washington University. He is an internationally recognized pioneer, scientist, clinician, and educator in integrative and metabolic medicine. Dr. Heyman is an influential voice advocating for meaningful change in conventional medicine by incorporating the best practices of traditional healing therapies and lifestyle medicine with the most advanced scientific approaches. He is triple-board-certified in family medicine, integrative medicine, and anti-aging and regenerative medicine.
Dr. Heyman received his Master of Health Services Administration from the University of Michigan School of Public Health. He completed his Family Medicine Residency at the University of Michigan Health System in 2007 and earned his medical degree from the University of Michigan Medical School in 2004. His extensive education and training have laid the foundation for his groundbreaking work in integrative medicine.
Throughout his career, Dr. Heyman has held several significant positions. He served as the national clinical working group co-chair of the Consortium of Academic Health Centers for Integrative Medicine and was the online editor for the Journal of Men's Health in the section of Integrative Medicine. Currently, he is the editor-in-chief of the Internet Journal of Anti-Aging and Aesthetic Medicine. His research interests focus on stress response and neuroendocrinology, cardiometabolic disease, men's health, and the impact of neuroinflammation and biotoxic exposures.
Dr. Harris serves as Amazon's Global Medical Director. He is a board-certified in Occupational and Environmental Medicine, Dr. Harris has over 15-years of medical device experience, provides advisory services to some of America’s largest companies and has made numerous media appearances.
Dr. Harris is the founder of HFit Health, which provides clinical and technical solutions to today’s workplace health challenges. Dr. Harris holds MD and MBA degrees from Indiana University, MPH from the University of Illinois at Chicago, and completed a fellowship in Biodesign & Innovation at the University of Missouri.